<rdf:RDF xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:digibug.ugr.es:10481/92081">
      <dc:title>Treatment resistance in pancreatic and biliary tract cancer: molecular and clinical pharmacology perspectives</dc:title>
      <dc:creator>Toledo, Belén</dc:creator>
      <dc:creator>Deiana, Chiara</dc:creator>
      <dc:creator>Scianò, Fabio</dc:creator>
      <dc:creator>Brandi, Giovanni</dc:creator>
      <dc:creator>Marchal Corrales, Juan Antonio</dc:creator>
      <dc:creator>Perán, Macarena</dc:creator>
      <dc:creator>Giovannetti, Elisa</dc:creator>
      <dc:subject>Biliary tract cancer</dc:subject>
      <dc:subject>Chemoresistance</dc:subject>
      <dc:subject>Chemotherapy</dc:subject>
      <dc:description>Introduction: Treatment resistance poses a significant obstacle in oncology, especially in biliary tract&#xd;
cancer (BTC) and pancreatic cancer (PC). Current therapeutic options include chemotherapy, targeted&#xd;
therapy, and immunotherapy. Resistance to these treatments may arise due to diverse molecular&#xd;
mechanisms, such as genetic and epigenetic modifications, altered drug metabolism and efflux, and&#xd;
changes in the tumor microenvironment. Identifying and overcoming these mechanisms is a major&#xd;
focus of research: strategies being explored include combination therapies, modulation of the tumor&#xd;
microenvironment, and personalized approaches.&#xd;
Areas covered: We provide a current overview and discussion of the most relevant mechanisms of&#xd;
resistance to chemotherapy, target therapy, and immunotherapy in both BTC and PC. Furthermore, we&#xd;
compare the different strategies that are being implemented to overcome these obstacles.&#xd;
Expert opinion: So far there is no unified theory on drug resistance and progress is limited. To&#xd;
overcome this issue, individualized patient approaches, possibly through liquid biopsies or single-cell&#xd;
transcriptome studies, are suggested, along with the potential use of artificial intelligence, to guide&#xd;
effective treatment strategies. Furthermore, we provide insights into what we consider the most&#xd;
promising areas of research, and we speculate on the future of managing treatment resistance to&#xd;
improve patient outcomes.</dc:description>
      <dc:date>2024-05-27T06:54:42Z</dc:date>
      <dc:date>2024-05-27T06:54:42Z</dc:date>
      <dc:date>2024-03-15</dc:date>
      <dc:type>journal article</dc:type>
      <dc:identifier>Belén Toledo, Chiara Deiana, Fabio Scianò, Giovanni Brandi, Juan Antonio Marchal, Macarena Perán &amp; Elisa Giovannetti (15 Mar 2024): Treatment resistance in pancreatic and biliary tract cancer: molecular and clinical pharmacology perspectives, Expert Review of Clinical Pharmacology, DOI: 10.1080/17512433.2024.2319340</dc:identifier>
      <dc:identifier>https://hdl.handle.net/10481/92081</dc:identifier>
      <dc:identifier>10.1080/17512433.2024.2319340</dc:identifier>
      <dc:language>eng</dc:language>
      <dc:rights>http://creativecommons.org/licenses/by-nc-nd/4.0/</dc:rights>
      <dc:rights>open access</dc:rights>
      <dc:rights>Attribution-NonCommercial-NoDerivatives 4.0 Internacional</dc:rights>
      <dc:publisher>Taylor &amp; Francis Group</dc:publisher>
   </ow:Publication>
</rdf:RDF>